Pfizer Inc (Extended Hours)

Pfizer's Hympavzi (marstacimab) gained FDA approval for hemophilia A and B in patients 12 and older, showing notable bleeding reduction in Phase 3 trials and offering a weekly treatment alternative.

Pfizer's COVID-19 vaccine for the KP.2 subvariant has received UK regulatory approval for adults following the International Recognition Procedure with the European Medicines Agency.

Morgan Stanley cut its price target on Pfizer, Inc. (PFE) from $31 to $30. Analysts give Pfizer an average outperform rating, with price targets ranging from $27 to $45.